Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.

Pasireotide in the treatment of neuroendocrine tumors: A review of the literature / G. Vitale, A. Dicitore, C. Sciammarella, S. Di Molfetta, M. Rubino, A. Faggiano, A. Colao. - In: ENDOCRINE-RELATED CANCER. - ISSN 1351-0088. - 25:6(2018 Jun), pp. R351-R364.

Pasireotide in the treatment of neuroendocrine tumors: A review of the literature

G. Vitale
Primo
;
A. Dicitore
Secondo
;
2018

Abstract

Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.
Neuroendocrine tumors; Pasireotide; Somatostatin analogs; Somatostatin receptors; Endocrinology, Diabetes and Metabolism; Oncology; Endocrinology; Cancer Research
Settore MED/13 - Endocrinologia
giu-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
ERC2018.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.34 MB
Formato Adobe PDF
1.34 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/587991
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 30
social impact